Introduction A mobile app may increase the reporting of adverse drug reactions (ADRs) and improve the communication of new drug safety information. Factors that influence the use of an app for such two-way risk communication need to be considered at the development stage. Objective Our aim was to reveal the factors that may influence healthcare professionals (HCPs) and patients to use an app for two-way risk communication. Methods Focus group discussions and face-to-face interviews were conducted in the Netherlands, Spain and the UK. Patients with type 2 diabetes mellitus, patients with a rare disease or their caregivers and adolescents with health conditions were eligible to participate. HCPs included pharmacists, paediatricians, general p...
The passive surveillance system is an important tool in pharmacovigilance of vaccines. However, repo...
Over a period of 3 years, the European Union's Innovative Medicines Initiative WEB-RADR (Recognising...
Over a period of 3 years, the European Union's Innovative Medicines Initiative WEB-RADR (Recognising...
Introduction A mobile app may increase the reporting of adverse drug reactions (ADRs) and improve th...
Introduction A mobile app may increase the reporting of adverse drug reactions (ADRs) and improve th...
Introduction A mobile app may increase the reporting of adverse drug reactions (ADRs) and improve th...
Previously, an app has been developed for healthcare professionals (HCPs) and patients to report adv...
Previously, an app has been developed for healthcare professionals (HCPs) and patients to report adv...
Previously, an app has been developed for healthcare professionals (HCPs) and patients to report adv...
Previously, an app has been developed for healthcare professionals (HCPs) and patients to report adv...
Over a period of 3 years, the European Union's Innovative Medicines Initiative WEB-RADR (Recognising...
Over a period of 3 years, the European Union's Innovative Medicines Initiative WEB-RADR (Recognising...
Recent years have seen a rapidly increasing trend towards the delivery of health technology through ...
International audienceIntroduction: Patient reporting adds value to pharmacovigilance. Encouraging i...
International audienceIntroduction: Patient reporting adds value to pharmacovigilance. Encouraging i...
The passive surveillance system is an important tool in pharmacovigilance of vaccines. However, repo...
Over a period of 3 years, the European Union's Innovative Medicines Initiative WEB-RADR (Recognising...
Over a period of 3 years, the European Union's Innovative Medicines Initiative WEB-RADR (Recognising...
Introduction A mobile app may increase the reporting of adverse drug reactions (ADRs) and improve th...
Introduction A mobile app may increase the reporting of adverse drug reactions (ADRs) and improve th...
Introduction A mobile app may increase the reporting of adverse drug reactions (ADRs) and improve th...
Previously, an app has been developed for healthcare professionals (HCPs) and patients to report adv...
Previously, an app has been developed for healthcare professionals (HCPs) and patients to report adv...
Previously, an app has been developed for healthcare professionals (HCPs) and patients to report adv...
Previously, an app has been developed for healthcare professionals (HCPs) and patients to report adv...
Over a period of 3 years, the European Union's Innovative Medicines Initiative WEB-RADR (Recognising...
Over a period of 3 years, the European Union's Innovative Medicines Initiative WEB-RADR (Recognising...
Recent years have seen a rapidly increasing trend towards the delivery of health technology through ...
International audienceIntroduction: Patient reporting adds value to pharmacovigilance. Encouraging i...
International audienceIntroduction: Patient reporting adds value to pharmacovigilance. Encouraging i...
The passive surveillance system is an important tool in pharmacovigilance of vaccines. However, repo...
Over a period of 3 years, the European Union's Innovative Medicines Initiative WEB-RADR (Recognising...
Over a period of 3 years, the European Union's Innovative Medicines Initiative WEB-RADR (Recognising...